泊沙康唑对伞枝犁头霉和米根霉活性增强的分子基础。
Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae.
作者信息
Chau Andrew S, Chen Guodong, McNicholas Paul M, Mann Paul A
机构信息
Schering-Plough Research Institute, 2015 Galloping Hill Road, 4700, Kenilworth, NJ 07033, USA.
出版信息
Antimicrob Agents Chemother. 2006 Nov;50(11):3917-9. doi: 10.1128/AAC.00747-06. Epub 2006 Sep 11.
Abstract
Posaconazole and itraconazole were more potent inhibitors of ergosterol synthesis, in both intact cells and cell extracts from Absidia corymbifera and Rhizopus oryzae, than voriconazole and fluconazole. Similarly, expression of CYP51 from R. oryzae in Saccharomyces cerevisiae significantly increased resistance to fluconazole and voriconazole but not to posaconazole and itraconazole.
摘要
在刺状犁头霉和米根霉的完整细胞及细胞提取物中，泊沙康唑和伊曲康唑对麦角固醇合成的抑制作用比伏立康唑和氟康唑更强。同样，米根霉的CYP51在酿酒酵母中的表达显著增加了对氟康唑和伏立康唑的耐药性，但对泊沙康唑和伊曲康唑没有影响。
相似文献
1
Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae.
Antimicrob Agents Chemother. 2006 Nov;50(11):3917-9. doi: 10.1128/AAC.00747-06. Epub 2006 Sep 11.
2
Activity of posaconazole in treatment of experimental disseminated zygomycosis.
Antimicrob Agents Chemother. 2003 Nov;47(11):3647-50. doi: 10.1128/AAC.47.11.3647-3650.2003.
3
Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes.
Mycoses. 2008 Mar;51(2):147-54. doi: 10.1111/j.1439-0507.2007.01457.x.
4
Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.
Antimicrob Agents Chemother. 2015 Dec;59(12):7830-2. doi: 10.1128/AAC.01583-15. Epub 2015 Sep 21.
5
Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.
Antimicrob Agents Chemother. 2004 Oct;48(10):3690-6. doi: 10.1128/AAC.48.10.3690-3696.2004.
6
Posaconazole prophylaxis in experimental systemic zygomycosis.
Antimicrob Agents Chemother. 2007 Jan;51(1):73-7. doi: 10.1128/AAC.00969-06. Epub 2006 Oct 23.
7
Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes.
J Antimicrob Chemother. 2005 Jun;55(6):1016-9. doi: 10.1093/jac/dki140. Epub 2005 May 9.
8
Characterization of a lanosterol 14 alpha-demethylase from Pneumocystis carinii.
Am J Respir Cell Mol Biol. 2003 Aug;29(2):232-8. doi: 10.1165/rcmb.2003-0012OC. Epub 2003 Feb 26.
9
In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility.
J Antimicrob Chemother. 2010 Oct;65(10):2158-63. doi: 10.1093/jac/dkq276. Epub 2010 Jul 28.
10
Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-bioassays and ergosterol quantification.
Rev Iberoam Micol. 2013 Jan 3;30(1):31-8. doi: 10.1016/j.riam.2012.09.006. Epub 2012 Oct 13.
引用本文的文献
1
Trans-kingdom fungal pathogens infecting both plants and humans, and the problem of azole fungicide resistance.
Front Microbiol. 2024 Feb 12;15:1354757. doi: 10.3389/fmicb.2024.1354757. eCollection 2024.
2
Whole genome analysis of species causing rhino-cerebral mucormycosis during the COVID-19 pandemic.
Front Cell Infect Microbiol. 2023 Oct 31;13:1251456. doi: 10.3389/fcimb.2023.1251456. eCollection 2023.
3
Antifungal properties of (2S, 4R)-Ketoconazole sulfonamide analogs.
Front Drug Discov (Lausanne). 2022;2. doi: 10.3389/fddsv.2022.1000827. Epub 2022 Aug 29.
4
In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China.
Infect Drug Resist. 2022 Apr 22;15:2101-2113. doi: 10.2147/IDR.S360191. eCollection 2022.
5
Recent Advances and Future Directions in the Understanding of Mucormycosis.
Front Cell Infect Microbiol. 2022 Feb 24;12:850581. doi: 10.3389/fcimb.2022.850581. eCollection 2022.
6
Roles for Structural Biology in the Discovery of Drugs and Agrochemicals Targeting Sterol 14α-Demethylases.
J Fungi (Basel). 2021 Jan 20;7(2):67. doi: 10.3390/jof7020067.
7
Molecular Confirmation of the Linkage between the Gene Coding Region and Its Intrinsic Voriconazole and Fluconazole Resistance.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00224-18. Print 2018 Aug.
8
Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved aminoacid substitution of the lanosterol 14α-demethylase.
Sci Rep. 2017 Nov 21;7(1):15898. doi: 10.1038/s41598-017-16123-9.
9
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Antimicrob Agents Chemother. 2014 Nov;58(11):6767-72. doi: 10.1128/AAC.03569-14. Epub 2014 Sep 2.
10
Pharmacokinetic/pharmacodynamic profile of posaconazole.
Clin Pharmacokinet. 2010 Jun;49(6):379-96. doi: 10.2165/11319340-000000000-00000.
本文引用的文献
1
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15. doi: 10.1128/AAC.00163-06.
2
Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole.
J Antimicrob Chemother. 2006 Jun;57(6):1235-9. doi: 10.1093/jac/dkl133. Epub 2006 Apr 20.
3
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.
Clin Infect Dis. 2006 Apr 1;42(7):e61-5. doi: 10.1086/500212. Epub 2006 Feb 21.
4
Posaconazole as salvage therapy for zygomycosis.
Antimicrob Agents Chemother. 2006 Jan;50(1):126-33. doi: 10.1128/AAC.50.1.126-133.2006.
5
Posaconazole: a broad-spectrum triazole antifungal.
Lancet Infect Dis. 2005 Dec;5(12):775-85. doi: 10.1016/S1473-3099(05)70297-8.
6
Epidemiology and outcome of zygomycosis: a review of 929 reported cases.
Clin Infect Dis. 2005 Sep 1;41(5):634-53. doi: 10.1086/432579. Epub 2005 Jul 29.
7
Effects of Y132H and F145L substitutions on the activity, azole resistance and spectral properties of Candida albicans sterol 14-demethylase P450 (CYP51): a live example showing the selection of altered P450 through interaction with environmental compounds.
J Biochem. 2005 May;137(5):625-32. doi: 10.1093/jb/mvi073.
8
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.
J Infect Dis. 2005 Apr 15;191(8):1350-60. doi: 10.1086/428780. Epub 2005 Mar 16.
9
Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.
Antimicrob Agents Chemother. 2004 Oct;48(10):3690-6. doi: 10.1128/AAC.48.10.3690-3696.2004.
10
Evaluation of fluconazole resistance mechanisms in candida albicans clinical isolates from HIV-infected patients in Brazil.
Diagn Microbiol Infect Dis. 2004 Sep;50(1):25-32. doi: 10.1016/j.diagmicrobio.2004.04.009.
Zotero 插件